GlobalData has predicted that the arrival of biosimilar therapies in the EU will continue to fall in the coming years following a wave pattern that has been occurring since 2006.   GlobalData’s senior drugs database analyst Quentin Horgan notes that we are currently in the downward trajectory of a wave that peaked in 2018, and it is likely […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!